Total Payments
$9,310
2024 Payments
$636.11
Companies
32
Transactions
416
Medicare Patients
4,678
Medicare Billing
$491,005
Payment Breakdown by Category
Food & Beverage$9,194 (98.8%)
Education$116.06 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,194 | 414 | 98.8% |
| Education | $116.06 | 2 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $2,155 | 77 | $0 (2024) |
| ABBVIE INC. | $1,869 | 76 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $960.71 | 49 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $518.81 | 27 | $0 (2024) |
| PFIZER INC. | $493.06 | 29 | $0 (2024) |
| Celgene Corporation | $469.60 | 45 | $0 (2023) |
| Gilead Sciences, Inc. | $366.34 | 17 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $249.98 | 2 | $0 (2022) |
| UCB, Inc. | $235.52 | 10 | $0 (2023) |
| INTERCEPT PHARMACEUTICALS, INC. | $213.54 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $636.11 | 20 | Janssen Biotech, Inc. ($170.02) |
| 2023 | $3,079 | 142 | ABBVIE INC. ($507.85) |
| 2022 | $3,412 | 149 | ABBVIE INC. ($972.00) |
| 2021 | $1,749 | 82 | Janssen Biotech, Inc. ($780.42) |
| 2020 | $183.23 | 10 | AbbVie Inc. ($79.53) |
| 2019 | $232.53 | 12 | Boston Scientific Corporation ($87.64) |
| 2018 | $17.98 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($17.98) |
All Payment Transactions
416 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $29.22 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Immunology | ||||||
| 12/13/2024 | American Regent | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $130.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $27.84 | General |
| 08/16/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/30/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/15/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/01/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/21/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $1.76 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 06/04/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Gastroenterology | ||||||
| 04/03/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/11/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $29.27 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/08/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $10.59 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 02/12/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/24/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 01/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: Gastroenterology | ||||||
| 01/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: Gastroenterology | ||||||
| 12/27/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/18/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $7.92 | General |
| Category: Gastroenterology | ||||||
| 11/28/2023 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/22/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/16/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Hepatology / Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,080 | 2,846 | $324,556 | $119,831 |
| 2022 | 22 | 1,264 | 3,618 | $369,127 | $127,980 |
| 2021 | 20 | 1,374 | 3,405 | $405,537 | $141,862 |
| 2020 | 18 | 960 | 1,142 | $268,342 | $101,332 |
Total Patients
4,678
Total Services
11,011
Medicare Billing
$491,005
Procedure Codes
82
All Medicare Procedures & Services
82 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 129 | 137 | $39,731 | $18,070 | 45.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 132 | 133 | $52,331 | $15,387 | 29.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 65 | 66 | $32,939 | $12,115 | 36.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 46 | 46 | $18,062 | $9,267 | 51.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 65 | 96 | $19,192 | $8,744 | 45.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 130 | 147 | $26,230 | $8,369 | 31.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 89 | 90 | $24,361 | $7,263 | 29.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 19 | 19 | $9,483 | $5,982 | 63.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 66 | 72 | $18,156 | $5,427 | 29.9% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 27 | 29 | $10,482 | $4,688 | 44.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 19 | 19 | $5,143 | $3,652 | 71.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 54 | 54 | $11,923 | $3,229 | 27.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 24 | 26 | $9,675 | $3,151 | 32.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 29 | 30 | $7,348 | $2,721 | 37.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 44 | $6,212 | $2,699 | 43.4% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 16 | 16 | $7,462 | $2,656 | 35.6% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 13 | 15 | $6,008 | $2,296 | 38.2% |
| 76700 | Complete ultrasound scan of abdomen | Office | 2023 | 32 | 35 | $5,524 | $1,657 | 30.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 34 | 34 | $4,865 | $1,254 | 25.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 23 | $2,551 | $831.90 | 32.6% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 17 | 1,700 | $986.00 | $199.05 | 20.2% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $5,890 | $174.10 | 3.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 142 | 149 | $42,941 | $22,573 | 52.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 98 | 99 | $50,614 | $19,278 | 38.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 177 | 179 | $74,377 | $18,741 | 25.2% |
About Mark Pinkhasov, D.O, PHARM-D
Mark Pinkhasov, D.O, PHARM-D is a Pharmacist healthcare provider based in Utica, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1528233756.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Pinkhasov, D.O, PHARM-D has received a total of $9,310 in payments from pharmaceutical and medical device companies, with $636.11 received in 2024. These payments were reported across 416 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($9,194).
As a Medicare-enrolled provider, Pinkhasov has provided services to 4,678 Medicare beneficiaries, totaling 11,011 services with total Medicare billing of $491,005. Data is available for 4 years (2020–2023), covering 82 distinct procedure/service records.
Ad
Practice Information
- Specialty Pharmacist
- Other Specialties Internal Medicine, Hepatology
- Location Utica, NY
- Active Since 04/29/2008
- Last Updated 06/25/2020
- Taxonomy Code 183500000X
- Entity Type Individual
- NPI Number 1528233756
Products in Payments
- STELARA (Biological) $2,137
- ENTYVIO (Biological) $849.09
- RINVOQ (Biological) $577.19
- ZEPOSIA (Drug) $564.62
- XELJANZ (Drug) $491.30
- SKYRIZI (Biological) $478.24
- XIFAXAN (Drug) $438.05
- HUMIRA (Biological) $302.54
- Cimzia (Drug) $235.52
- OCALIVA (Drug) $213.54
- IBSRELA (Drug) $178.33
- DUPIXENT (Biological) $170.72
- TREMFYA (Drug) $170.02
- CREON (Drug) $168.07
- Linzess (Drug) $154.25
- LINZESS (Drug) $141.93
- ZENPEP (Drug) $137.55
- VOQUEZNA (Drug) $130.00
- GATTEX (Drug) $111.50
- ERBE (Device) $108.58
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pharmacist Doctors in Utica
Mr. Robert Petronio, Rph, RPH
Pharmacist
Pharmacist
Dr. Joshua Schomer, Pharmd, PHARMD
Pharmacist
Pharmacist
Mr. William Dunn, Rph, RPH
Pharmacist
Pharmacist
Dr. Melanie Main, Pharmd, Rph, PHARMD, RPH
Pharmacist
Pharmacist
Mrs. Geraldine Gates, R.ph, R.PH
Pharmacist
Pharmacist
Mrs. Deborah Mazza, Rph, RPH
Pharmacist
Pharmacist